v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2026
Dec. 31, 2025
Current assets:    
Cash $ 3,250,650 $ 5,106,872
Prepaid insurance 56,031 26,682
Other prepaid expenses 101,069 44,825
Total current assets 3,407,750 5,178,379
LiGHT proton therapy system equipment 6,607,419 6,582,560
Operating lease right-of-use assets 850,129 972,682
Total assets 10,865,298 12,733,621
Current liabilities:    
Accounts payable and accrued expenses, including $37,390 and $125,959 to related parties at March 31, 2026 and December 31, 2025, respectively 391,081 436,482
Research and development contract liabilities 238,435 232,138
Operating lease obligations, current 595,418 595,418
Series B Convertible Preferred Stock 8% cumulative dividend payable 69,073
Total current liabilities 1,224,934 1,333,111
Operating lease obligations, long-term 461,772 438,959
Total liabilities 1,686,706 1,772,070
Commitments and Contingencies
Common stock, $0.0001 par value; 100,000,000 shares authorized; 11,632,944 and 8,790,102 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 1,162 879
Additional paid-in capital 67,944,759 66,008,824
Accumulated deficit (60,000,889) (58,077,213)
Total Lixte Biotechnology stockholders’ equity 7,945,032 9,664,059
Non-controlling interest 1,233,560 1,297,492
Total stockholders’ equity 9,178,592 10,961,551
Total liabilities and stockholders’ equity 10,865,298 12,733,621
Series A Convertible Preferred Stock [Member]    
Current liabilities:    
Preferred Stock value
Series B Convertible Preferred Stock [Member]    
Current liabilities:    
Preferred Stock value $ 1,731,569

Source

HTML PDF
ZIP